The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Open accessAbstract
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per year in the United States alone. The hallmark of ALL is chromosomal abnormalities and genetic alterations involved in differentiation and proliferation of lymphoid precursor cells. In adults, 75% of cases develop from precursors of the B-cell lineage, with the remainder of cases consisting of malignant T-cell precursors. Traditionally, risk stratification has been based on clinical factors such age, white blood cell count and response to chemotherapy; however, the identification of recurrent genetic alterations has helped refine individual prognosis and guide management. Despite advances in management, the backbone of therapy remains multi-agent chemotherapy with vincristine, corticosteroids and an anthracycline with allogeneic stem cell transplantation for eligible candidates. Elderly patients are often unable to tolerate such regimens and carry a particularly poor prognosis. Here, we review the major recent advances in the treatment of ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,801
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,377
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G., Durrant, I. J., Luger, S. M., Marks, D. I., Franklin, I. M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Moorman, A. V., Harrison, C. J., Buck, G. A. N., Richards, S. M., Secker-Walker, L. M., Martineau, M., Vance, G. H., Cherry, A. M., Higgins, R. R., Fielding, A. K., et al. (2007) · Blood · doi:10.1182/blood-2006-10-051912 · Cited by 753
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Holmfeldt, L., Wei, L., Diaz-Flores, E., Walsh, M., Zhang, J., Ding, L., Payne-Turner, D., Churchman, M., Andersson, A., Chen, S.-C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2532 · Cited by 731
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Larson, R., Dodge, R., Burns, C., Lee, E., Stone, R., Schulman, P., Duggan, D., Davey, F., Sobol, R., & Frankel, Sr. (1995) · Blood · doi:10.1182/blood.v85.8.2025.bloodjournal8582025 · Cited by 626
Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A. A., Loudin, M. G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R. C., Willman, C. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.469 · Cited by 623
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Thomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
Huguet, F., Leguay, T., Raffoux, E., Thomas, X., Beldjord, K., Delabesse, E., Chevallier, P., Buzyn, A., Delannoy, A., Chalandon, Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6916 · Cited by 567
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
Thomas, X., Boiron, J.-M., Huguet, F., Dombret, H., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.050 · Cited by 550
Brüggemann, M., Raff, T., Flohr, T., Gökbuget, N., Nakao, M., Droese, J., Lüschen, S., Pott, C., Ritgen, M., Scheuring, U., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2708 · Cited by 537
Stock, W., La, M., Sanford, B., Bloomfield, C. D., Vardiman, J. W., Gaynon, P., Larson, R. A., & Nachman, J. (2008) · Blood · doi:10.1182/blood-2008-01-130237 · Cited by 534
van Dongen, J. J. M., van der Velden, V. H. J., Brüggemann, M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2015-03-580027 · Cited by 511
Gökbuget, N., Kneba, M., Raff, T., Trautmann, H., Bartram, C.-R., Arnold, R., Fietkau, R., Freund, M., Ganser, A., Ludwig, W.-D., et al. (2012) · Blood · doi:10.1182/blood-2011-09-377713 · Cited by 493
Foà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351403 · Cited by 462
Porkka, K., Koskenvesa, P., Lundán, T., Rimpiläinen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., et al. (2008) · Blood · doi:10.1182/blood-2008-02-140665 · Cited by 445
Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E. M., Terruzzi, E., et al. (2009) · Blood · doi:10.1182/blood-2008-11-185132 · Cited by 430
Thomas, D. A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J. L., Bueso-Ramos, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9456 · Cited by 416
Kantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M., Faderl, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70386-2 · Cited by 412
Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R. A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A. M., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073528 · Cited by 366
Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1182 · Cited by 366
DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
Blinatumomab: A historical perspective
Nagorsen, D., Kufer, P., Baeuerle, P. A., & Bargou, R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.013 · Cited by 355
Jain, N., Lamb, A. V., O’Brien, S., Ravandi, F., Konopleva, M., Jabbour, E., Zuo, Z., Jorgensen, J., Lin, P., Pierce, S., et al. (2016) · Blood · doi:10.1182/blood-2015-08-661702 · Cited by 352
Advani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1900 · Cited by 336
Bloom's syndrome. XX. The first 100 cancers
German, J. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00336-6 · Cited by 317
Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer
Widdison, W. C., Wilhelm, S. D., Cavanagh, E. E., Whiteman, K. R., Leece, B. A., Kovtun, Y., Goldmacher, V. S., Xie, H., Steeves, R. M., Lutz, R. J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060319f · Cited by 309
Kantarjian, H., Thomas, D., Jorgensen, J., Kebriaei, P., Jabbour, E., Rytting, M., York, S., Ravandi, F., Garris, R., Kwari, M., et al. (2013) · Cancer · doi:10.1002/cncr.28136 · Cited by 306
DNA Methylation as a Therapeutic Target in Cancer
Issa, J.-P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2076 · Cited by 301
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Dai, H., Wang, Y., Lu, X., & Han, W. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv439 · Cited by 299
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine
Hunger, S. P., & Mullighan, C. G. (2015) · Blood · doi:10.1182/blood-2015-02-580043 · Cited by 292
Fielding, A. K., Rowe, J. M., Richards, S. M., Buck, G., Moorman, A. V., Durrant, I. J., Marks, D. I., McMillan, A. K., Litzow, M. R., Lazarus, H. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199380 · Cited by 291
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Maude, S. L., Tasian, S. K., Vincent, T., Hall, J. W., Sheen, C., Roberts, K. G., Seif, A. E., Barrett, D. M., Chen, I.-M., Collins, J. R., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415448 · Cited by 289
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
Jabbour, E., O'Brien, S., Konopleva, M., & Kantarjian, H. (2015) · Cancer · doi:10.1002/cncr.29383 · Cited by 285
Adult Acute Lymphoblastic Leukemia
Paul, S., Kantarjian, H., & Jabbour, E. J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.09.010 · Cited by 275
Dhédin, N., Huynh, A., Maury, S., Tabrizi, R., Beldjord, K., Asnafi, V., Thomas, X., Chevallier, P., Nguyen, S., Coiteux, V., et al. (2015) · Blood · doi:10.1182/blood-2014-09-599894 · Cited by 270
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., & Taylor, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900632 · Cited by 262
Short, N. J., Jabbour, E., Sasaki, K., Patel, K., O’Brien, S. M., Cortes, J. E., Garris, R., Issa, G. C., Garcia-Manero, G., Luthra, R., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707562 · Cited by 260
Tavernier, E., Boiron, J.-M., Huguet, F., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404824 · Cited by 256
Acute Lymphoblastic Leukemia, Version 2.2015
Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Barta, S. K., Borate, U., Boyer, M. W., Burke, P. W., Cassaday, R., Castro, J. E., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0153 · Cited by 243
Raff, T., Gökbuget, N., Lüschen, S., Reutzel, R., Ritgen, M., Irmer, S., Böttcher, S., Horst, H.-A., Kneba, M., Hoelzer, D., et al. (2007) · Blood · doi:10.1182/blood-2006-07-037093 · Cited by 240
Tasian, S. K., Doral, M. Y., Borowitz, M. J., Wood, B. L., Chen, I.-M., Harvey, R. C., Gastier-Foster, J. M., Willman, C. L., Hunger, S. P., Mullighan, C. G., et al. (2012) · Blood · doi:10.1182/blood-2011-12-389932 · Cited by 240
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Kreitman, R. J., & Pastan, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0487 · Cited by 231
Akslen, L. A., & LiVolsi, V. A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000415)88:8<1964::aid-cncr27>3.0.co;2-1 · Cited by 231
Ravandi, F., O'Brien, S. M., Cortes, J. E., Thomas, D. M., Garris, R., Faderl, S., Burger, J. A., Rytting, M. E., Ferrajoli, A., Wierda, W. G., et al. (2015) · Cancer · doi:10.1002/cncr.29646 · Cited by 227
Raetz, E. A., Cairo, M. S., Borowitz, M. J., Blaney, S. M., Krailo, M. D., Leil, T. A., Reid, J. M., Goldenberg, D. M., Wegener, W. A., Carroll, W. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3528 · Cited by 208
Messinger, Y. H., Gaynon, P. S., Sposto, R., van der Giessen, J., Eckroth, E., Malvar, J., & Bostrom, B. C. (2012) · Blood · doi:10.1182/blood-2012-04-418640 · Cited by 205
Ravandi, F., Jorgensen, J. L., Thomas, D. A., O’Brien, S., Garris, R., Faderl, S., Huang, X., Wen, S., Burger, J. A., Ferrajoli, A., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466482 · Cited by 205
Sasaki, K., Jabbour, E. J., Ravandi, F., Short, N. J., Thomas, D. A., Garcia‐Manero, G., Daver, N. G., Kadia, T. M., Konopleva, M. Y., Jain, N., et al. (2016) · Cancer · doi:10.1002/cncr.30231 · Cited by 204
O'Brien, S., Schiller, G., Lister, J., Damon, L., Goldberg, S., Aulitzky, W., Ben-Yehuda, D., Stock, W., Coutre, S., Douer, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2309 · Cited by 196
Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias
Cortes, J., Thomas, D., Koller, C., Giles, F., Estey, E., Faderl, S., Garcia-Manero, G., McConkey, D., Patel, G., Guerciolini, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0508 · Cited by 194
The biology and therapy of adult acute lymphoblastic leukemia
Faderl, S., Jeha, S., & Kantarjian, H. M. (2003) · Cancer · doi:10.1002/cncr.11664 · Cited by 193
Carnahan, J. F., Wang, P., Kendall, R. L., Chen, C., Hu, S., Boone, T., Juan, T., Talvenheimo, J., Montestruque, S., Sun, J., et al. (2003) · PubMed · Cited by 185
Characterization of CD22 expression in acute lymphoblastic leukemia
Shah, N. N., Stevenson, M. S., Yuan, C. M., Richards, K., Delbrook, C., Kreitman, R. J., Pastan, I., & Wayne, A. S. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25410 · Cited by 179
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
Smith, E. J., Olson, K., Haber, L. J., Varghese, B., Duramad, P., Tustian, A. D., Oyejide, A., Kirshner, J. R., Canova, L., Menon, J., et al. (2015) · Scientific Reports · doi:10.1038/srep17943 · Cited by 167
Wierda, W. G., Padmanabhan, S., Chan, G. W., Gupta, I. V., Lisby, S., Österborg, A., & for the Hx-CD20-406 Study Investigators (2011) · Blood · doi:10.1182/blood-2011-04-348656 · Cited by 160
Outcome of adults with acute lymphocytic leukemia after second salvage therapy
O'Brien, S. M., Thomas, D. M., Ravandi, F., Faderl, S. H., Cortes, J. E., Borthakur, G., Pierce, S. A., Garcia‐Manero, G., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23919 · Cited by 150
Jones, B., Freeman, A. I., Shuster, J. J., Jacquillat, C., Weil, M., Pochedly, C., Sinks, L. F., Chevalier, L., Maurer, H. M., Koch, K., et al. (1991) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950190411 · Cited by 150
Milani, L. A., Lundmark, A., Kiialainen, A., Nordlund, J., Flægstad, T., Forestier, E., Heyman, M. M., Jónmundsson, G., Kanerva, J. A., Schmiegelow, K., et al. (2009) · Blood · doi:10.1182/blood-2009-04-214668 · Cited by 146
Prognostic factors in adult acute lymphoblastic leukaemia
Rowe, J. M. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08246.x · Cited by 144
Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia
Faderl, S. H., Kantarjian, H. M., Thomas, D. A., et al. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009148847 · Cited by 140
Grupp, S. A., Maude, S. L., Shaw, P. A., Aplenc, R., Barrett, D. M., Callahan, C. A., Lacey, S. F., Levine, B. L., Melenhorst, J. J., Motley, L. S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.681.681 · Cited by 140
Jones, D. M., Thomas, D. M., Yin, C. C., O'Brien, S. M., Cortes, J. E., Jabbour, E. J., Breeden, M., Giles, F. J., Zhao, W., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23666 · Cited by 137
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
Horton, T. M., Gannavarapu, A., Blaney, S. M., D’Argenio, D. Z., Plon, S. E., & Berg, S. L. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0135-z · Cited by 134
Rytting, M., Jabbour, E. J., Jorgensen, J. L., Ravandi, F., Franklin, A. R. K., Kadia, T. M., Pemmaraju, N., Daver, N. G., Ferrajoli, A., Garcia‐Manero, G., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24419 · Cited by 131
CD19-dependent Activation of Akt Kinase in B-lymphocytes
Otero, D. C., Omori, S. A., & Rickert, R. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m003918200 · Cited by 126
Flynn, M. J., Zammarchi, F., Tyrer, P. C., Akarca, A. U., Janghra, N., Britten, C. E., Havenith, C. E. G., Levy, J.-N., Tiberghien, A. C., Masterson, L. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0233 · Cited by 124
Fujimoto, M., Poe, J. C., Jansen, P. J., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.12.7088 · Cited by 122
Chiarini, F., Falà, F., Tazzari, P. L., Ricci, F., Astolfi, A., Pession, A., Pagliaro, P., McCubrey, J. A., & Martelli, A. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4884 · Cited by 120
Barrett, D. M., Liu, X., Jiang, S., June, C. H., Grupp, S. A., & Zhao, Y. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.075 · Cited by 114
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Campana, D. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.001 · Cited by 113
Laport, G. G., Alvarnas, J., Palmer, J. M., et al. (2008) · Blood · doi:10.1182/blood-2008-03-143115 · Cited by 109
Stock, W., Luger, S. M., Advani, A. S., Geyer, S. M., Harvey, R. C., Mullighan, C. G., Willman, C. L., Malnassy, G., Parker, E., Laumann, K. M., et al. (2014) · Blood · doi:10.1182/blood.v124.21.796.796 · Cited by 105
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways
Zhao, W.-L. (2009) · Leukemia · doi:10.1038/leu.2009.223 · Cited by 100
CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis
Chung, E. Y., Psathas, J. N., Yu, D., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45851 · Cited by 94
Piccaluga, P. P., Arpinati, M., Candoni, A., Laterza, C., Paolini, S., Gazzola, A., Sabattini, E., Visani, G., & Pileri, S. A. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.529206 · Cited by 92
Herrera, L., Bostrom, B., Gore, L., Sandler, E. S., Lew, G., Schlegel, P. G., Aquino, V., Ghetie, V. F., Vitetta, E. S., & Schindler, J. D. (2009) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181bdf211 · Cited by 91
Schindler, J. D., Gajavelli, S., Ravandi, F., Shen, Y.-M. P., Parekh, S. S., Braunchweig, I., Barta, S. K., Ghetie, V. F., Vitetta, E. S., & Verma, A. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08762.x · Cited by 89
DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia
Nordlund, J., Bäcklin, C. L., Zachariadis, V., Cavelier, L. B., Dahlberg, J., Öfverholm, I. I., Barbany, G., Nordgren, A., Övernäs, E., Abrahamsson, J., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-014-0039-z · Cited by 78
Wayne, A. S., Shah, N. N., Bhojwani, D., et al. (2017) · Blood · doi:10.1182/blood-2017-02-749101 · Cited by 71
Coelho, V., Krysov, S. V., Steele, A. J., Sánchéz‐Hidalgo, M., Johnson, P., Chana, P. S., Packham, G., Stevenson, F. K., & Forconi, F. (2013) · Blood · doi:10.1182/blood-2013-02-485425 · Cited by 69
Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies
Sharkey, R. M., Govindan, S. V., Cardillo, T. M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0632 · Cited by 68
Bressanin, D., Evangelisti, C., Ricci, F., Tabellini, G., Chiarini, F., Tazzari, P. L., Melchionda, F., Buontempo, F., Pagliaro, P., Pession, A., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.579 · Cited by 68
Kantarjian, H. M., Lioure, B., Kim, S. K., Atallah, E. L., Leguay, T., Kelly, K., Marolleau, J., Escoffre‐Barbe, M., Thomas, X., Cortes, J. E., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.12.004 · Cited by 68
Saunders, P. O., Cisterne, A., Weiss, J., Bradstock, K. F., & Bendall, L. J. (2010) · Haematologica · doi:10.3324/haematol.2010.026997 · Cited by 58
Epigenetic deregulation in pediatric acute lymphoblastic leukemia
Chatterton, Z., Morenos, L., Mechinaud, F. M., Ashley, D. M., Craig, J. M., Sexton‐Oates, A., Halemba, M. S., Parkinson-Bates, M., Ng, J., Morrison, D. J., et al. (2014) · Epigenetics · doi:10.4161/epi.27585 · Cited by 57
Benton, C. B., Thomas, D. A., Yang, H., Ravandi, F., Rytting, M., O'Brien, S. M., Franklin, A. R. K., Borthakur, G. M., Dara, S., Kwari, M. I., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13050 · Cited by 53
Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M. S., Brüggemann, M., Horst, H. A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.680.680 · Cited by 53
Riët, T., Holzinger, A., Dörrie, J., Schaft, N., Schuler, G., & Abken, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_12 · Cited by 49
Schult, C., Dahlhaus, M., Glass, Ä., Fischer, K. J., Lange, S., Freund, M., & Junghanß, C. (2012) · PubMed · Cited by 49
Treatment of acute lymphoblastic leukemia in adults
Narayanan, S., & Shami, P. J. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.01.014 · Cited by 47
XLF deficiency results in reduced N-nucleotide addition during V(D)J recombination
IJspeert, H., Rozmus, J., Schwarz, K., Warren, R. L., van Zessen, D. B. H., Holt, R. A., Pico‐Knijnenburg, I., Simons, E. J., Jerchel, I. S., Wawer, A., et al. (2016) · Blood · doi:10.1182/blood-2016-02-701029 · Cited by 45
Nordlund, J., Milani, L. A., Lundmark, A., Lönnerholm, G., & Syvänen, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034513 · Cited by 42
Genetic modification of lymphocytes by retrovirus-based vectors
Suerth, J. D., Schambach, A., & Baum, C. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.007 · Cited by 38
Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia
Yáñez, L., Bermúdez, A., Richard, C., Bureo, E., & Iriondo, A. (2009) · Leukemia · doi:10.1038/leu.2009.58 · Cited by 33
Lu, B. Y., Thanawala, S. U., Zochowski, K. C., Burke, M. J., Carroll, W. L., & Bhatla, T. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1110747 · Cited by 30
Spector, L. G., Ross, J. A., Robison, L. L., & Bhatia, S. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.004 · Cited by 21
Zammarchi, F., Williams, D. G., Adams, L. R., Havenith, K., Chivers, S., D’Hooge, F., Howard, P. W., Hartley, J. A., & van Berkel, P. H. (2015) · Blood · doi:10.1182/blood.v126.23.1564.1564 · Cited by 10
Cited by
Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01222-8 · Cited by 820
Clinical update on head and neck cancer: molecular biology and ongoing challenges
Alsahafi, E., Begg, K., Amelio, I., Raulf, N., Lucarelli, P., Sauter, T., & Tavassoli, M. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1769-9 · Cited by 525
Mäder, P., & Kattner, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00960 · Cited by 438
Integrating evolutionary dynamics into cancer therapy
Gatenby, R. A., & Brown, J. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0411-1 · Cited by 227
Small Non-Coding RNAs in Leukemia
Balatti, V., & Croce, C. M. (2022) · Cancers · doi:10.3390/cancers14030509 · Cited by 14
Metadata
- Authors
- Terwilliger, T., & Abdul-Hay, M.
- Venue
- Blood Cancer Journal
- Published
- 2017-06-30
- Volume
- 7
- Issue
- 6
- Pages
- e577-e577
- ISSN
- 2044-5385 (ISSN-L)
- OpenAlex
- W2725970815
- Cited by
- 1,288
- References
- 122
- FWCI
- 80.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.